210 related articles for article (PubMed ID: 24615121)
21. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells.
Le Magnen C; Bubendorf L; Ruiz C; Zlobec I; Bachmann A; Heberer M; Spagnoli GC; Wyler S; Mengus C
Eur J Cancer; 2013 Mar; 49(4):955-63. PubMed ID: 23089465
[TBL] [Abstract][Full Text] [Related]
22. iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.
Rehman I; Evans CA; Glen A; Cross SS; Eaton CL; Down J; Pesce G; Phillips JT; Yen OS; Thalmann GN; Wright PC; Hamdy FC
PLoS One; 2012; 7(2):e30885. PubMed ID: 22355332
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus.
Plum PS; Ulase D; Bollschweiler E; Chon SH; Berlth F; Zander T; Alakus H; Hölscher AH; Bruns CJ; Schallenberg S; Quaas A; Loeser H
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1731-1739. PubMed ID: 29974234
[TBL] [Abstract][Full Text] [Related]
24. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
25. Inhibitor of DNA binding-1 overexpression in prostate cancer: relevance to tumor differentiation.
Yu X; Xu X; Han B; Zhou R
Pathol Oncol Res; 2009 Mar; 15(1):91-6. PubMed ID: 18752043
[TBL] [Abstract][Full Text] [Related]
26. Underexpression of MMP-2 and its regulators, TIMP2, MT1-MMP and IL-8, is associated with prostate cancer.
Reis ST; Antunes AA; Pontes-Junior J; Sousa-Canavez JM; Dall'Oglio MF; Piantino CB; Cruz JA; Morais DR; Srougi M; Leite KR
Int Braz J Urol; 2012; 38(2):167-74. PubMed ID: 22555040
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
28. [Expression of insulin-like growth factor 2 mRNA-binding protein 3 expression and analysis of prognosis in the patients with lung squamous cell carcinoma].
Lin L; Zhang J; Wang Y; Zheng L; Lin Z; Cai Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jul; 29(7):694-7. PubMed ID: 23837977
[TBL] [Abstract][Full Text] [Related]
29. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia.
Zhong W; Peng J; He H; Wu D; Han Z; Bi X; Dai Q
Clin Invest Med; 2008; 31(1):E8-E15. PubMed ID: 18312749
[TBL] [Abstract][Full Text] [Related]
30. Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma.
Yuan RH; Wang CC; Chou CC; Chang KJ; Lee PH; Jeng YM
Ann Surg Oncol; 2009 Jun; 16(6):1711-9. PubMed ID: 19357927
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the clinical value of the newly identified urine biomarker HIST1H4K for diagnosis and prognosis of prostate cancer in Bulgarian patients.
Kachakova D; Mitkova A; Popov E; Beltcheva O; Vlahova A; Dikov T; Hristova S; Mitev V; Slavov C; Kaneva R
J BUON; 2013; 18(3):660-8. PubMed ID: 24065480
[TBL] [Abstract][Full Text] [Related]
32. Altered staining patterns and expression level of Engrailed-2 in benign prostatic hyperplasia and prostate Cancer predict prostatic disease progression.
Li Q; Shi Y; Sa R; Hao J; Hu J; Xiao M; Wang C; Yan L; Qiao B; Chen G
BMC Cancer; 2020 Jun; 20(1):555. PubMed ID: 32539763
[TBL] [Abstract][Full Text] [Related]
33. Expression and significance of S100P, CD147, and OCT4 in different prostate cancer tissue TNM stages.
Wang Q; Zhang JG; Wang W
Genet Mol Res; 2015 Jun; 14(2):6844-51. PubMed ID: 26125892
[TBL] [Abstract][Full Text] [Related]
34. Expression of NGF, GDNF and MMP-9 in prostate carcinoma.
Baspinar S; Bircan S; Ciris M; Karahan N; Bozkurt KK
Pathol Res Pract; 2017 May; 213(5):483-489. PubMed ID: 28237042
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
36. The relation of beclin 1 and bcl-2 expressions in high grade prostatic intraepithelial neoplasia and prostate adenocarcinoma: a tissue microarray study.
Baspinar S; Bircan S; Orhan H; Kapucuoglu N; Bozkurt KK
Pathol Res Pract; 2014 Jul; 210(7):412-8. PubMed ID: 24690321
[TBL] [Abstract][Full Text] [Related]
37. Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.
Szarvas T; Reis H; Vom Dorp F; Tschirdewahn S; Niedworok C; Nyirady P; Schmid KW; Rübben H; Kovalszky I
Prostate; 2016 Aug; 76(11):977-85. PubMed ID: 27062540
[TBL] [Abstract][Full Text] [Related]
38. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
39. Nedd4L expression is downregulated in prostate cancer compared to benign prostatic hyperplasia.
Hu XY; Xu YM; Fu Q; Yu JJ; Huang J
Eur J Surg Oncol; 2009 May; 35(5):527-31. PubMed ID: 19004604
[TBL] [Abstract][Full Text] [Related]
40. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F
Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
